• Explore /
  • Poster
  • / Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors.

Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors.

Abstract Poster

Authors

null

Zev A. Wainberg

Ronald Regan UCLA Medical Center, Los Angeles, CA

Zev A. Wainberg , Peter D. Eisenberg , Jasgit C. Sachdev , Amy M. Weise , David Ross Kaufman , Marguerite Hutchinson , Sandra Tong , Ireene Aromin , Siwen Hu-Lieskovan , Amita Patnaik

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Translational Research

Clinical Trial Registration Number

NCT02452424

Citation

J Clin Oncol 34, 2016 (suppl 4S; abstr TPS465)

DOI

10.1200/jco.2016.34.4_suppl.tps465

Abstract #

TPS465

Poster Bd #

N15

Abstract Disclosures

Similar Posters

First Author: Amita Patnaik

First Author: Georgina V. Long

First Author: Panpan Zhang

First Author: Jiaxin Niu